Cardiff Oncology (CRDF) Equity Ratio (2016 - 2025)
Cardiff Oncology (CRDF) has disclosed Equity Ratio for 15 consecutive years, with 0.73 as the latest value for Q4 2025.
- Quarterly Equity Ratio fell 14.06% to 0.73 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.73 through Dec 2025, down 14.06% year-over-year, with the annual reading at 0.73 for FY2025, 14.06% down from the prior year.
- Equity Ratio hit 0.73 in Q4 2025 for Cardiff Oncology, down from 0.76 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.97 in Q2 2021 to a low of 0.73 in Q4 2025.
- Historically, Equity Ratio has averaged 0.87 across 5 years, with a median of 0.88 in 2023.
- Biggest five-year swings in Equity Ratio: surged 85.34% in 2021 and later fell 14.06% in 2025.
- Year by year, Equity Ratio stood at 0.94 in 2021, then decreased by 2.53% to 0.92 in 2022, then fell by 6.66% to 0.85 in 2023, then decreased by 0.09% to 0.85 in 2024, then dropped by 14.06% to 0.73 in 2025.
- Business Quant data shows Equity Ratio for CRDF at 0.73 in Q4 2025, 0.76 in Q3 2025, and 0.77 in Q2 2025.